Straits Times Index
3,272.72 +47.55 (+1.47%) S&P 500
5,070.55 +59.95 (+1.20%) Dow
38,503.69 +263.71 (+0.69%) Nasdaq
15,696.64 +245.33 (+1.59%) Bitcoin USD
66,446.90 -441.23 (-0.66%) CMC Crypto 200
1,427.94 +13.18 (+0.93%)
REGN Jan 2025 490.000 call
| Previous close | 320.00 |
| Open | 320.00 |
| Bid | 312.10 |
| Ask | 319.90 |
| Strike | 490.00 |
| Expiry date | 2025-01-17 |
| Day's range | 320.00 - 320.00 |
| Contract range | N/A |
| Volume | |
| Open interest | 2 |
GlobeNewswireRegeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT)
Oral presentations include updated results from clinical study of otoferlin gene therapy DB-OTO demonstrating restoration in children with profound genetic hearing loss Additional presentations cover progress in novel genetic medicine delivery systems and immune response modulation TARRYTOWN, N.Y., April 22, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new and updated data across its genetic medicines portfolio will be presented at the American Soc
ZacksAgenus (AGEN) Soars 6.8%: Is Further Upside Left in the Stock?
Agenus (AGEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Simply Wall St.Regeneron Pharmaceuticals Insiders Sell US$26m Of Stock, Possibly Signalling Caution
Over the past year, many Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) insiders sold a significant stake in the...
